Randomized phase III study comparing gefitinib (G) with erlotinib (E) in patients (pts) with previously treated advanced lung adenocarcinoma (LA): WJOG 5108L.
Nobuyuki Katakami(Takarazuka City Hospital), Junya Inata, Toshiaki Takahashi(Okayama University), Miyako Satouchi(Memorial Sloan Kettering Cancer Center), Hiroshige Yoshioka(Harbin Medical University), Yoichi Nakanishi(Kyushu University), Tetsuya Oguri(Miyoshi Kasei (Japan)), Toshiyuki Kozuki(Shikoku Cancer Center), Isao Goto, Haruko Daga(Osaka City General Hospital), Shunichi Sugawara(Sendai Kousei Hospital), Yoshiko Urata(Miyoshi Kasei (Japan)), Kazuhiko Nakagawa(Osaka Red Cross Hospital), Satoshi Morita(Kyoto University), Yasuo Iwamoto(Hiroshima City Asa Citizens Hospital), Norihiko Ikeda(Tokyo Medical University), Chiyoe Kitagawa(Nagoya Medical Center), Takashi Seto(National Hospital Organization Kyushu Cancer Center), Junji Uchida(Osaka Prefectural Medical Center), Kojiro Otsuka(Shinko Hospital)
Cited by 11
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k